Worldometer. COVID – Coronavirus Statistics – Worldometer. https://www.worldometers.info/coronavirus/.
Msemburi, W. et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613, 130–137 (2023).
Thomas, C. et al. Lived experience of patients with Long COVID: a qualitative study in the UK. BMJ Open 13, e068481 (2023).
Owen, R. et al. Acute COVID-19, the Lived Experience, and Lessons to Learn for Future Pandemics. Disaster Med. Public Health Prep. 17, e534 (2023).
Kogevinas, M. et al. Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia. BMC Med. 23, 140 (2025). In a prospective population-based cohort of 2,764 SARS-CoV-2-infected adults from Catalonia, Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia found that 23% developed long-COVID symptoms between 2021–2023, more than half of whom still had symptoms after two years, and that risk was significantly elevated in women, younger individuals, those with severe acute infection, obesity, asthma/COPD or mental-health disorders, while prior vaccination.
Ma, Y. et al. Long-term consequences of asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Int. J. Environ. Res. Public. Health 20, 1613 (2023).
Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023).
Al-Aly, Z. & Topol, E. Solving the puzzle of long Covid. Science 383, 830–832 (2024).
Callard, F. & Perego, E. How and why patients made Long Covid. Soc. Sci. Med. 268, 113426 (2021).
Greenhalgh, T., Sivan, M., Perlowski, A. & Nikolich, J. Ž. Long COVID: a clinical update. Lancet 404, 707-724 (2024).
Organisation, W. H. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2021).
Kim, Y., Bae, S., Chang, H.-H. & Kim, S.-W. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci. Rep. 13, 11207 (2023). Seventy-one percent of participants reported at least one long-COVID symptom at 24 months post-infection, and around one-third continued to experience reduced neuropsychiatric quality of life despite improvement over time, highlighting the long-term and ongoing impact of even mild acute COVID‑19 on survivors’ daily living.
Dehlia, A. & Guthridge, M. A. The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: a systematic review and meta-analysis. J. Infect. 89, 106297 (2024).
Hornig, M. et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci. Adv. 1, e1400121 (2015).
Thomas, C. et al. Blood biomarkers of long COVID: a systematic review. Mol. Diagn. Ther. 28, 537–574 (2024).
Liew, F. et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat. Immunol. 25, 607–621 (2024).
Al-Aly, Z. et al. Long COVID science, research and policy | Nature Medicine. https://www.nature.com/articles/s41591-024-03173-6 (2024).
Faghy, M. A. et al. Is Long COVID the next global health crisis? J. Glob. Health (In Press).
Faghy, M. A. et al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore pre-COVID quality of life. Expert Rev. Respir. Med. 16, 595–600 (2022).
Zhang, S. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. J. Hematol. Oncol. 13, 120 (2020).
Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling. Nature 623, 139–148 (2023). Individuals with long COVID exhibit distinct immune-profile signatures, such as altered myeloid and lymphocyte populations, elevated SARS-CoV-2 and reactivated Epstein–Barr virus antibody responses, and reduced cortisol levels, which together may serve as biomarkers and provide insight into the pathobiology of the condition.
Montazersaheb, S. et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol. J. 19, 92 (2022).
Del Giudice, M. & Gangestad, S. W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain. Behav. Immun. 70, 61–75 (2018).
Friedman, E. M., Hayney, M., Love, G. D., Singer, B. H. & Ryff, C. D. Plasma interleukin-6 and soluble IL-6 receptors are associated with psychological well-being in aging women. Health Psychol. 26, 305 (2007).
Giannitrapani, L. et al. Can baseline IL-6 levels predict long COVID in subjects hospitalized for SARS-CoV-2 disease?. Int. J. Mol. Sci. 24, 1731 (2023).
Son, K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 61, 2200970 (2023).
Schultheiß, C. et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 (2022).
Patel, M. A. et al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol. Med. 28, 122 (2022).
Patel, M. A. et al. Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Mol. Med. 29, 26 (2023).
Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol. 1, 17 (2023).
Proal, A. D. et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat. Immunol. 1–12 (2023). Evidence that SARS-CoV-2 RNA and/or proteins persist in tissues long after acute infection, proposes that such viral reservoirs may drive chronic symptoms via immune, coagulation and microbiome dysregulation, and underscores the importance of targeting viral persistence in the search for therapies for Long COVID.
Proal, A. D. et al. Targeting the SARS-CoV-2 reservoir in long COVID. Lancet Infect. Dis. 25, e294–e306 (2025).
Proal, A. D. & VanElzakker, M. B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 12, 1494 (2021).
Gil, A. et al. Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series. Brain Behav. Immun. Health 36, 100720 (2024).
Patterson, B. K. et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front. Immunol. 12, 5526 (2022).
Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881–895 (2022).
Santopaolo, M. et al. Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months. Elife 12, e85009 (2023).
Patterson, B. K. et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front. Immunol. 12, 2520 (2021).
Scott, N. A. et al. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID. Eur. Respir. J. 61, 2202226 (2023).
Fujinami, R. S. Viruses and autoimmune disease–two sides of the same coin?. TRENDS Microbiol. 9, 377–381 (2001).
Sfriso, P. et al. Infections and autoimmunity: the multifaceted relationship. J. Leukoc. Biol. 87, 385–395 (2010).
Sharma, C. & Bayry, J. High risk of autoimmune diseases after COVID-19. Nat. Rev. Rheumatol. 1–2 https://doi.org/10.1038/s41584-023-00964-y (2023).
Wuller, S. et al. Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. PloS One 20, e0324513 (2025). Individuals who experienced more severe acute SARS‑CoV‑2 infection had a significantly higher risk of developing new autoimmune diseases, such as thyroid disease, psoriasis/psoriatic arthritis, inflammatory bowel disease, and (in children) type 1 diabetes, within up to two years post‑infection, highlighting the severity of initial COVID‑19 illness as a potential predictor and modifiable risk factor for autoimmune sequelae.
Wee, L. E. et al. Autoimmune sequelae after delta or omicron variant SARS-CoV-2 infection in a highly vaccinated cohort. JAMA Netw. Open 7, e2430983–e2430983 (2024).
Chang, R. et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56, (2023).
Hileman, C. O., Malakooti, S. K., Patil, N., Singer, N. G. & McComsey, G. A. New-onset autoimmune disease after COVID-19. Front. Immunol. 15, (2024).
Dotan, A. & Shoenfeld, Y. Chapter 13 – Autoimmunity on the Rise: COVID-19 as a Trigger of Autoimmunity. in Infection and Autoimmunity (Third Edition) (eds Mahroum, N., Watad, A. & Shoenfeld, Y.) 247–257 (Academic Press, Amsterdam, 2024). https://doi.org/10.1016/B978-0-323-99130-8.00030-1.
Wekerle, H. & Hohlfeld, R. Molecular mimicry in multiple sclerosis. N. Engl. J. Med. 349, 185–185 (2003).
Talwar, S., Harker, J. A., Openshaw, P. J. M. & Thwaites, R. S. Autoimmunity in long COVID. J. Allergy Clin. Immunol. 155, 1082–1094 (2025).
Weinstock, L. B. et al. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 112, 217–226 (2021).
Bastard, P. et al. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol. Rev. 322, 98–112 (2024).
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
Mouton, W. et al. Immunological and Clinical Markers of Post-acute Sequelae of COVID-19: Insights from Mild and Severe Cases 6 Months Post-infection. Eur. J. Immunol. 55, e51948 (2025). Whilst most humoral, viral, and tissue‑damage biomarkers at 6–9 months after acute COVID‑19 were driven by initial illness severity rather than the presence of post‑acute sequelae (PASC), individuals with PASC exhibited distinctive T‑cell signatures, specifically higher cytokine‑secreting CD4⁺/CD8⁺ memory T cells and increased terminally differentiated CD45RA⁺ TEMRA cells responsive to SARS‑CoV‑2 nucleocapsid/membrane proteins, suggesting a potential immunological marker set for long‑term symptom persistence.
Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat. Commun. 15, 8941 (2024).
Rojas, M. et al. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 20, 129 (2022).
Seeßle, J. et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): a Prospective Cohort Study. Clin. Infect. Dis. 74, 1191–1198 (2022).
Sotzny, F. et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front. Immunol. 13, (2022). Individuals with post‑COVID syndrome (PCS) exhibited altered serum levels of autoantibodies against vaso‑ and immunoregulatory G‑protein‑coupled receptors (GPCRs). Notably including those targeting ADRB2, STAB1 and ADRA2A, with several of these autoantibody levels correlating with symptom severity (e.g., fatigue and vasomotor symptoms) and thus implicating immune‑ and vascular‑dysregulation pathways as potential contributors to PCS.
Hofmann, S. et al. Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID. Int. J. Mol. Sci. 26, 6746 (2025).
Wallukat, G. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 4, 100100 (2021).
Maguire, C. et al. Analysis of 977 Long COVID Patients Reveals Prevalent Neuropathy and Association with Anti-Ganglioside Antibodies. MedRxiv Prepr. Serv. Health Sci. 2025.03.04.25323101 https://doi.org/10.1101/2025.03.04.25323101 (2025).
Gavrilova, N. Y. et al. Autoantigens of Small Nerve Fibers and Human Coronavirus Antigens: Is There a Possibility for Molecular Mimicry?. Curr. Microbiol. 81, 366 (2024).
Hatayama, Y. et al. Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis. Int. J. Mol. Sci. 26, 1751 (2025).
Matula, Z. et al. High prevalence of long COVID in anti-TPO positive euthyroid individuals with strongly elevated SARS-CoV-2-specific T cell responses and moderately raised anti-spike IgG levels 23 months post-infection. Front. Immunol. 15, 1448659 (2024).
Muri, J. et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat. Immunol. 24, 604–611 (2023).
Scheibenbogen, C. et al. Immunoadsorption to remove ß2 adrenergic receptor antibodies in chronic fatigue syndrome CFS/ME. PLoS One 13, e0193672 (2018).
Stein, E. et al. Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Reg. Heal. 49, 101161 (2025).
Dorst, J. Apheresis in neurological disorders. J. Clin. Med. 9, 3211 (2020).
Achleitner, M. et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol. Psychiatry 28, 2872–2877 (2023).
España-Cueto, S. et al. Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. Nat. Commun. 16, 1929 (2025).
Morse, B. A., Motovilov, K., Michael Brode, W., Michael Tee, F. & Melamed, E. A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome. Brain. Behav. Immun. 123, 725–738 (2025).
Thompson, J. S., Thornton, A. C., Ainger, T. & Garvy, B. A. Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front. Immunol. 13, 1033651 (2022).
Hogeweg, M. et al. Intravenous immunoglobulins in the treatment of post-COVID: a case-control study. J. Intern. Med. 293, 656–658 (2023).
Hohberger, B. et al. Case report: neutralization of autoantibodies targeting G-protein-coupled receptors improves capillary impairment and fatigue symptoms after COVID-19 infection. Front. Med. 8, 754667 (2021).
Hohberger, B. et al. Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT). EClinicalMedicine 86, 103358 (2025).
Bonilla, H. et al. Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front. Immunol. 14, 1129459 (2023).
Li, Z., You, Y., Griffin, N., Feng, J. & Shan, F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int. Immunopharmacol. 61, 178–184 (2018).
Tamariz, L., Bast, E., Klimas, N. & Palacio, A. Low-dose naltrexone improves post-COVID-19 condition symptoms. Clin. Ther. 46, e101–e106 (2024).
Isman, A. et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav. Immun. Health 36, 100733 (2024).
O’Kelly, B. et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav. Immun. Health 24, 100485 (2022).
Bonilla, H. et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int. Immunopharmacol. 124, 110966 (2023).
Acosta-Ampudia, Y. et al. Persistent autoimmune activation and proinflammatory state in post-Coronavirus disease 2019 syndrome. J. Infect. Dis. 225, 2155–2162 (2022).
Kell, D. B. & Pretorius, E. Are fibrinaloid microclots a cause of autoimmunity in long Covid and other post-infection diseases?. Biochem. J. 480, 1217–1240 (2023).
Hromić-Jahjefendić, A. et al. The intersection of microbiome and autoimmunity in long COVID-19: current insights and future directions. Cytokine Growth Factor Rev. 82, 43–54 (2025).
Adiguzel, Y., Bogdanos, D. P. & Shoenfeld, Y. Molecular/antigenic mimicry and immunological cross-reactivity explains SARS-CoV-2-induced autoimmunity. Autoimmun. Rev. 24, 103811 (2025).
Peluso, M. J. et al. Plasma-based antigen persistence in the post-acute phase of COVID-19. Lancet Infect. Dis. 24, e345–e347 (2024). SARS‑CoV‑2 antigens (notably spike and nucleocapsid) were detectable in plasma up to 14 months after acute infection at significantly higher rates than in pre‑pandemic controls. Providing compelling evidence for persistent viral antigenemia in the post‑acute phase of COVID‑19 and underscoring a potential mechanism for ongoing symptomatology in long COVID.
Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911–923 (2022).
Appelman, B. et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat. Commun. 15, 17 (2024). Patients with Long COVID showing post‑exertional malaise (PEM) exhibited marked skeletal‑muscle abnormalities, including increased glycolytic fibre composition, reduced mitochondrial oxidative‑phosphorylation capacity, amyloid‑containing deposit accumulation and exercise‑induced myopathy. These abnormalities worsened following an exercise challenge, thereby offering direct mechanistic insight into how PEM may contribute to impaired functional capacity in Long COVID.
Hawley, H. B. Long COVID: clinical findings, pathology, and endothelial molecular mechanisms. Am. J. Med. https://www.sciencedirect.com/science/article/pii/S0002934323005399 (2023).
Wu, Y. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol. Hepatol. 5, 434–435 (2020).
Cheung, C. C. L. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 71, 226–229 (2021).
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 3, 371–387.e9 (2022).
Scott, J. T. et al. Post-Ebola syndrome, Sierra Leone. Emerg. Infect. Dis. 22, 641 (2016).
Dokubo, E. K. et al. Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. Lancet Infect. Dis. 18, 1015–1024 (2018).
Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758–763 (2022).
Yong, S. J. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem. Neurosci. 12, 573–580 (2021).
Swank, Z. et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin. Infect. Dis. 76, e487–e490 (2023).
Peluso, M. J. et al. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. medRxiv 2023–10 (2023).
Craddock, V. et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J. Med. Virol. 95, e28568 (2023).
Peluso, M. J. et al. Multimodal molecular imaging reveals tissue-based T cell activation and viral RNA persistence for up to 2 years following COVID-19. medRxiv https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418298/ (2023).
Peluso, M. J. et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 133, e163669 (2023).
Maguire, C. et al. Chronic viral reactivation and associated host immune response and clinical outcomes in acute COVID-19 and post-acute sequelae of COVID-19. bioRxiv https://doi.org/10.1101/2024.11.14.622799 (2024).
Vojdani, A., Vojdani, E., Saidara, E. & Maes, M. Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses 15, 400 (2023).
Bernal, K. D. E. & Whitehurst, C. B. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. 334, 199157 (2023).
Swank, Z. et al. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study. Clin. Microbiol. Infect. 30, 1599–1605 (2024).
Rendeiro, A. F. et al. The spatial landscape of lung pathology during COVID-19 progression. Nature 593, 564–569 (2021).
Cross, A. R. et al. Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury. JCI Insight 8, e157837 (2023).
Chen, B., Julg, B., Mohandas, S. & Bradfute, S. B. Viral persistence, reactivation, and mechanisms of long COVID. Elife 12, e86015 (2023).
Kruger, A. et al. Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Semin. Thromb. Hemost. 51, 256–271 (2024).
Haffke, M. et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J. Transl. Med. 20, 138 (2022).
Charfeddine, S. et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front. Cardiovasc. Med. 8, 1702 (2021).
Kruger, A. et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol. 21, 190 (2022).
Jarrott, B., Head, R., Pringle, K. G., Lumbers, E. R. & Martin, J. H. “LONG COVID”—a hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 10, e00911 (2022).
Vollenberg, R. et al. Indications of persistent glycocalyx damage in convalescent COVID-19 patients: a prospective multicenter study and hypothesis. Viruses 13, 2324 (2021).
Osiaevi, I. et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis 26, 53–61 (2023).
Willems, L. H. et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb. Res. 209, 106–114 (2022).
Wang, C. et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell. Infect. Microbiol. 12, 861703 (2022).
Hawley, H. B. & Chang, J. C. Complement-induced endotheliopathy–associated vascular microthrombosis in coronavirus disease 2019. J. Infect. Dis. 223, 2198–2199 (2021).
Kell, D. B. & Pretorius, E. The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem. J. 479, 1653–1708 (2022).
Kell, D. B., Khan, M. A., Kane, B., Lip, G. Y. H. & Pretorius, E. Possible role of fibrinaloid microclots in postural orthostatic tachycardia syndrome (POTS): focus on long COVID. J. Pers. Med. 14, 170 (2024).
Fahmy, O. H. et al. Is microthrombosis the main pathology in coronavirus disease 2019 severity?—a systematic review of the postmortem pathologic findings. Crit. Care Explor. 3, e0427 (2021).
Pretorius, E. et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 20, 172 (2021).
Kell, D. B., Laubscher, G. J. & Pretorius, E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem. J. 479, 537–559 (2022).
Thomas, C. et al. Exercise-induced changes in microclotting and cytokine levels point to vascular injury and inflammation in people with long COVID. https://www.researchsquare.com/article/rs-6717727/latest (2025).
Lee, C. et al. Prevalence of orthostatic intolerance in long covid clinic patients and healthy volunteers: a multicenter study. J. Med. Virol. 96, e29486 (2024).
Smith, J. J., Porth, C. M. & Erickson, M. Hemodynamic response to the upright posture. J. Clin. Pharmacol. 34, 375–386 (1994).
Arnold, A. C., Ng, J. & Raj, S. R. Postural tachycardia syndrome–diagnosis, physiology, and prognosis. Auton. Neurosci. 215, 3–11 (2018).
Raj, S. R. et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 111, 1574–1582 (2005).
Raj, S. R. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol. J. 6, 84 (2006).
Vernino, S. et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting-Part 1. Auton. Neurosci. 235, 102828 (2021).
Sheldon, R. S. et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12, e41–e63 (2015).
Levine, T. D. Small fiber neuropathy: disease classification beyond pain and burning. J. Cent. Nerv. Syst. Dis. 10, 117957351877170 (2018).
Raj, S. R. Postural tachycardia syndrome (POTS). Circulation 127, 2336–2342 (2013).
Pons, S., Fodil, S., Azoulay, E. & Zafrani, L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit. Care 24, 353 (2020).
Chelazzi, C., Villa, G., Mancinelli, P., De Gaudio, A. R. & Adembri, C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit. Care 19, 26 (2015).
Finsterer, J. Re:‘Vagus nerve dysfunction in the post-COVID-19 condition’by Lladós et al. Clin. Microbiol. Infect. 30, 969–970 (2024).
Pietranis, K. A., Kostro, A. M., Dzięcioł-Anikiej, Z., Moskal-Jasińska, D. & Kuryliszyn-Moskal, A. Impact of COVID-19 on diaphragmatic function: understanding multiorgan involvement and long-term consequences. J. Clin. Med. 13, 6493 (2024).
Goldstein, D. S. Linking the extended autonomic system with the homeostat theory: new perspectives about dysautonomias. J. Pers. Med. 14, 123 (2024).
Woo, M. S. et al. Vagus nerve inflammation contributes to dysautonomia in COVID-19. Acta Neuropathol. 146, 387–394 (2023).
Andersson, U. & Tracey, K. J. Vagus nerve SARS-CoV-2 infection and inflammatory reflex dysfunction: is there a causal relationship?. J. Intern. Med. 295, 91–102 (2024).
Andersson, J. The inflammatory reflex – introduction. J. Intern. Med. 257, 122–125 (2005).
De Virgiliis, F. & Di Giovanni, S. Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19. Nat. Rev. Neurol. 16, 645–652 (2020).
Greene, C. et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat. Neurosci. 27, 421–432 (2024). Individuals with long COVID who report cognitive impairment show persistent disruption of the blood-brain barrier (BBB), alongside sustained systemic inflammation and coagulation dysregulation, suggesting BBB dysfunction may be a key mechanistic underpinning of neurocognitive sequelae in Long COVID.
Fekete, R. et al. Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1-and IL-6-related systemic inflammation in COVID-19. Nat. Neurosci. 28, 558–576 (2025).
Matschke, J. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 19, 919–929 (2020).
Beckman, D. et al. SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19. Cell Rep. 41, 111573 (2022).
Crunfli, F. et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc. Natl. Acad. Sci. USA 119, e2200960119 (2022).
Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 218, e20202135 (2021).
Dubé, M. et al. Axonal transport enables neuron-to-neuron propagation of human coronavirus. J. Virol. 92, OC43 (2018).
Jacomy, H. & Talbot, P. J. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology 315, 20–33 (2003).
Matsuda, K. et al. The vagus nerve is one route of transneural invasion for intranasally inoculated influenza A virus in mice. Vet. Pathol. 41, 101–107 (2004).
Guo Yong, G. Y., Korteweg, C., McNutt, M. A. & Gu Jiang, G. J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 133, 4–12 (2008).
Rong, Z. et al. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Cell Host Microbe 32, 2112–2130.e10 (2024).
Wong, A. C. et al. Serotonin reduction in post-acute sequelae of viral infection. Cell 186, 4851–4867.e20 (2023).
Gelbard, H. A. & Chiang, W. SARS and synapses. Nat. Microbiol. 9, 1163–1164 (2024).
Partiot, E. et al. Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis. Nat. Microbiol. 9, 1189–1206 (2024).
Tanaka, N. et al. Air trapping at CT: high prevalence in asymptomatic subjects with normal pulmonary function. Radiology 227, 776–785 (2003).
Cho, J. L. et al. Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Radiology 304, 185–192 (2022).
Guler, S. A. et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur. Respir. J. 57, 2003690 (2021).
Kavanagh, B. P. & Hedenstierna, G. Respiratory physiology and pathophysiology. Mill. Anesth. 8, 444–472 (2015).
Wild, J. M. et al. Review of hyperpolarized pulmonary functional 129Xe MR for long-COVID. J. Magn. Reson. Imaging 59, 1120–1134 (2024).
Dhawan, R. T. et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir. Med. 9, 107–116 (2021).
Screaton, N. Commentary: pulmonary vasculopathy in post-acute-COVID-19 syndrome—insights from dual-energy CT angiography. Eur. Radiol. 33, 4698–4699 (2023).
Thaweethai, T. et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 329, 1934–1946 (2023).
Vøllestad, N. K. & Mengshoel, A. M. Post-exertional malaise in daily life and experimental exercise models in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front. Physiol. 14, 1257557 (2023).
Medicine, I. of, Populations, B. on the H. of S. & Syndrome, C. on the D. C. for M. E. F. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. (National Academies Press, 2015).
Eckey, M., Li, P., Morrison, B., Davis, R. W. & Xiao, W. Patient-reported treatment outcomes in ME/CFS and long COVID. medRxiv 2024–11 (2024).
Walitt, B. et al. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nat. Commun. 15, 907 (2024).
Thomas, C. et al. Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and post-exertional symptom exacerbation in people with long COVID. Exp. Physiol. https://doi.org/10.1113/EP092415 (2025).
Charlton, B. T. et al. Skeletal muscle adaptations and post-exertional malaise in long COVID. Trends Endocrinol. Metab. 36, 614–622 (2024).
Colosio, M. et al. Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection. J. Appl. Physiol. 135, 902–917 (2023).
Hejbøl, E. K. et al. Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: evidence of skeletal muscle histopathology. Eur. J. Neurol. 29, 2832–2841 (2022).
de Boer, E. et al. Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome. Am. J. Respir. Crit. Care Med. 205, 126–129.
Guntur, V. P. et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC). Metabolites 12, 1026 (2022).
Faghy, M. A. et al The physiologic benefits of optimizing cardiorespiratory fitness and physical activity–From the cell to systems level in a post-pandemic world. Prog. Cardiovasc. Dis. https://www.sciencedirect.com/science/article/pii/S0033062024000288?casa_token=TURJGk_Ov4MAAAAA:VTYZ3re_MZ7h0jhAEj3FBFCRZ3knHbpiKs76YseTCDa-4ac0x9RY_29i7o1NQEre5u7X8UE (2024).
Díaz-Resendiz, K. J. G. et al. Loss of mitochondrial membrane potential (Δ Ψ m) in leucocytes as post-COVID-19 sequelae. J. Leukoc. Biol. 112, 23–29 (2022).
Guarnieri, J. W. et al. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci. Transl. Med. 15, eabq1533 (2023).
Wang, P. et al. WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl. Acad. Sci. 120, e2302738120 (2023).
Aschman, T. et al. Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles. Acta Neuropathol. Commun. 11, 193 (2023).
van Rhijn-Brouwer, F. C. C.-C. et al. Graded exercise therapy should not be recommended for patients with post-exertional malaise. Nat. Rev. Cardiol. 21, 430–431 (2024).
Guide, C. T. & Goldstein, J. David Tuller responds to the PACE investigators. http://www.cfstreatmentguide.com/blog/category/pace%20trial/2 (2015).
Racaniello, V. et al. Major breakthrough on PACE trial. https://citizen-network.org/news/major-breakthrough-on-pace-trial.
Matthees, A., Kindlon, T., Maryhew, C., Stark, P. & Levin, B. No ‘Recovery’ in PACE trial, new analysis finds. https://virology.ws/2016/09/21/no-recovery-in-pace-trial-new-analysis-finds/ (2016).
Leurent, B. expert reaction to results from REGAIN trial looking at an online supervised group physical and mental health rehabilitation programme for adults with long Covid after Covid hospitalisation | Science Media Centre. https://www.sciencemediacentre.org/expert-reaction-to-results-from-regain-trial-looking-at-an-online-supervised-group-physical-and-mental-health-rehabilitation-programme-for-adults-with-long-covid-after-covid-hospitalisation/ (2024).
Organization, W. H. Clinical Management of COVID-19: Living Guideline, 13 January 2023. https://apps.who.int/iris/bitstream/handle/10665/365580/WHO-2019-nCoV-clinical-2023.1-eng.pdf (2023).
Davenport, T. E., Stevens, S. R., VanNess, J. M., Stevens, J. & Snell, C. R. Checking our blind spots: current status of research evidence summaries in ME/CFS. Br. J. Sports Med. 53, 1198–1198 (2019).
Torjesen, I. NICE cautions against using graded exercise therapy for patients recovering from COVID-19. BMJ 370, m2912 (2020).
Vink, M. & Vink-Niese, A. The updated NICE guidance exposed the serious flaws in CBT and graded exercise therapy trials for ME/CFS. Healthcare 10, 898 (2022).
World Physiotherapy. World Physiotherapy Response to COVID-19 Briefing Paper 9. Safe rehabilitation approaches for people living with Long COVID: physical activity and exercise. https://www.google.com/search?q=world+physio+guidelines+graded+exercise+therapy&sca_esv=7035ff6bfa45f4a8&rlz=1C1ONGR_enGB1012GB1012&sxsrf=ADLYWILBVImkHiI5HsE_-1J20A9KurnvMw%3A1722510955017&ei=a26rZpJk6baFsg-u7qCQBQ&oq=world+physio+guidelines+graded+exercise+th&gs_lp=Egxnd3Mtd2l6LXNlcnAiKndvcmxkIHBoeXNpbyBndWlkZWxpbmVzIGdyYWRlZCBleGVyY2lzZSB0aCoCCAAyBRAhGKABMgUQIRigATIFECEYoAFIwjFQ9AhY-SpwAngBkAEAmAGCAaAB9giqAQQxMC4yuAEDyAEA-AEBmAIOoAKjCcICChAAGLADGNYEGEfCAgcQIRigARgKwgIEECEYFZgDAIgGAZAGCJIHBDEwLjSgB5cq&sclient=gws-wiz-serp (2021).
Goudsmit, E. M., Nijs, J., Jason, L. A. & Wallman, K. E. Pacing as a strategy to improve energy management in myalgic encephalomyelitis/chronic fatigue syndrome: a consensus document. Disabil. Rehabil. 34, 1140–1147 (2012).
Jason, L. A., Evans, M., So, S., Scott, J. & Brown, A. Problems in defining post-exertional malaise. J. Prev. Interv. Community 43, 20–31 (2015).
Faghy, P. M. A., Ashton, D. R. E., McNelis, M. R., Arena, R. & Duncan, D. R. Attenuating post-exertional malaise in Myalgic encephalomyelitis/chronic fatigue syndrome and long-COVID: is blood lactate monitoring the answer?. Curr. Probl. Cardiol. 49, 102554 (2024).
Mooren, F. C. et al. Autonomic dysregulation in long-term patients suffering from post-COVID-19 Syndrome assessed by heart rate variability. Sci. Rep. 13, 15814 (2023).
Faghy, M. A. et al. Developing effective strategies to optimize physical activity and cardiorespiratory fitness in the long Covid population: the need for caution and objective assessment. Prog. Cardiovasc. Dis. https://www.sciencedirect.com/science/article/pii/S0033062024000392 (2024).
Sarkanen, T. et al. Association between hypersomnolence and the COVID-19 pandemic: the International COVID-19 Sleep Study (ICOSS). Sleep. Med. 107, 108–115 (2023).
Jackson, C. et al. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. Lancet Respir. Med. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00124-8/fulltext?s=09 (2023).
Alzueta, E. et al. An international study of post-COVID sleep health. Sleep. Health 8, 684–690 (2022).
Rouen, A. et al. Polysomnographic parameters in long-COVID chronic insomnia patients. Dialogues Clin. Neurosci. 25, 43–49 (2023).
Gagliano, A. et al. Artificial neural networks analysis of polysomnographic and clinical features in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): from sleep alteration to “Brain Fog”. Nat. Sci. Sleep 13, 1209–1224 (2021).
Gómez-Benito, M. et al. Modeling Parkinson’s disease with the alpha-synuclein protein. Front. Pharmacol. 11, 356 (2020).
Moura, A. E. F. et al. Central hypersomnia and chronic insomnia: expanding the spectrum of sleep disorders in long COVID syndrome – a prospective cohort study. BMC Neurol. 22, 417 (2022).
Breen, J. J. et al. Navigating the path forward for evidence-based management of long COVID. Nat. Immunol. 26, 536–539 (2025).
Ely, E. W., Brown, L. M. & Fineberg, H. V. Long Covid defined. N. Engl. J. Med. 391, 1746–1753 (2024).
Grobbelaar, L. M. et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci. Rep. 41, BSR20210611 (2021).
Grobbelaar, L. M. et al. Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. Semin. Thromb. Hemost. 48, 858–868 (2022).
